CGRP and the Trigeminal System in Migraine
Headache The Journal of Head and Face Pain2019Vol. 59(5), pp. 659–681
Citations Over TimeTop 1% of 2019 papers
Abstract
CGRP plays an essential role in the pathophysiology of migraine. Treatments that interfere with the functioning of CGRP in the peripheral trigeminal system are effective against migraine. Blocking sensitization of the trigeminal nerve by attenuating CGRP activity in the periphery may be sufficient to block a migraine attack. Additionally, the potential exists that this therapeutic strategy may also alleviate cluster headache as well.
Related Papers
- → Differential distribution of calcitonin gene-related peptide and its receptor components in the human trigeminal ganglion(2010)334 cited
- → Coexistence of calcitonin gene-related peptide and substance P-like peptide in single cells of the trigeminal ganglion of the rat: immunohistochemical analysis(1985)368 cited
- → The role of calcitonin gene-related peptide on the increase in transient receptor potential vanilloid-1 levels in trigeminal ganglion and trigeminal nucleus caudalis activation of rat(2012)20 cited
- → The Anti-CGRP Antibody Fremanezumab Reduces Trigeminal Neurons Immunoreactive for CGRP and CGRP Receptor Components in Rat(2023)2 cited
- Changes of Nerve Growth Factor and Calcitonin Gene-Related Peptide in Trigeminal Ganglia after Teeth Injury(2002)